The DOI matches its Crossref record.
Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC
Abstract
Background KRAS is a known oncogenic driver in non-small cell lung cancer (NSCLC), with KRAS G12C and G12V mutations occurring in ~13% and ~7% of the of NSCLC ( adenocarcinoma subtype). The dual RAF-MEK inhibitor VS-6766 has shown single agent activity against G12V KRAS mutated NSCLC (Guo C et al Lancet Oncology 2020, 21:1478-88). Based on pre-clinical data, we hypothesised that augmented focal adhesion kinase (FAK) signalling is a mechanism of resistance to MEK inhibition and devised the current clinical trial. We have previously reported the safety of an intermittent schedule of the combination of VS-6766 and the FAK inhibitor defactinib and its efficacy in low grade serous ovarian cancer (Shinde et al., AACR 2020). We now report the activity of the combination in KRAS mutated NSCLC. Methods Patients were treated with an intermittent dose of drugs VS-6766 at 3.2 - 4 mg twice a week and defactinib 200 mg twice daily in the dose escalation and expansion cohorts of the study. Both drugs were administered three weeks on/one week off in 28-day cycles. We aim to recruit 20 patients with KRAS mutated NSCLC in an expansion cohort. Results To date, 19 patients with KRAS mutated NSCLC have been treated in the dose escalation and expansion cohorts. All patients had been previously treatment with a PD-1 or PDL-1 targeting immune checkpoint inhibitor. The median age was 64 years (22 - 73), M/F ratio was 7/12, and the median prior lines of treatment was 3. Currently, 17 of 19 patients have had at least one re-staging assessment, 2/17 (12%) patients had a partial response and 10/17 (59%) had stable disease as their best response. Of note, 11/17 (65%) patients had a degree of reduction in size of their tumours and 5/17 (29%) have been treated for 6 months or more with 3 patients still on treatment. Interestingly, 2/2 (100%) of the KRAS G12V NSCLC patients showed a partial response. Conclusions Developing new treatments for non-G12C KRAS mutated NSCLC is an area of unmet need. The combination of VS-6766 and defactinib treatment in cohorts of patients with NSCLC pre-treated with chemotherapy and immunotherapy has shown anti-tumour activity in subsets of patients with KRAS mutated NSCLC, in particular those with tumours harbouring KRAS G12V mutations. A registration-directed study evaluating VS-6766 ± defactinib for treatment of recurrent NSCLC with KRAS G12V mutation (NCT04620330) has been initiated Citation Format: Matthew G. Krebs, Rajiv Shinde, Rozana Abdul Rahman, Rafael Grochot, Martin Little, Jenny King, Joseph Kitchin, Mona Parmar, Alison Turner, Muneeb Mahmud, Christina Yap, Nina Tunariu, Juanita Lopez, Johann S. De Bono, Udai Banerji, Anna Minchom. A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT019.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The combination of avutometinib and the FAK inhibitor defactinib has demonstrated clinical ef fi cacy in both KRAS-mutated NSCLC and low-grade serous ovarian cancer (LGSOC) [18 -20].”
In the citing paper
“In this phase I/II trial, the objective response rate to combination therapy was 15.0% in patients with KRAS-mutated NSCLC and 44.8% in those with LGSOC [18, 19, 48, 49].”
In the citing paper
“In contrast, combination therapy with avutometinib and defactinib was generally well-tolerated in a phase I trial (NCT03875820) [18, 48].”
In the citing paper
“VS-6766 is currently studied in combination with the FAK inhibitor defactinib in KRAS-mutated NSCLC, yielding promising early responses with partial responses being observed in two NSCLC patients with KRASG12V-mutated cancers (58).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [58]
Citations
Cites
Still being checked.
Cited by
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
Li, S., Correia, G. S. D. C., Wang, J., Manochakian, R., Zhao, Y., & Lou, Y. (2023) · Cancers · doi:10.3390/cancers15112899 · Cited by 72
Strategies targeting tumor immune and stromal microenvironment and their clinical relevance
Hu, M., & Huang, L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114137 · Cited by 67
Capelletto, E., Bironzo, P., Denis, L. J., Koustenis, A. G., Bungaro, M., & Novello, S. (2022) · Future Oncology · doi:10.2217/fon-2021-1582 · Cited by 28
Metadata
- Authors
- Krebs, M. G., Shinde, R., Rahman, R. A., Grochot, R., Little, M., King, J., Kitchin, J., Parmar, M., Turner, A., Mahmud, M., Yap, C., Tunariu, N., Lopez, J., De Bono, J. S., Banerji, U., & Minchom, A.
- Affiliations
- University of Manchester (GB)
- Royal Marsden Hospital (GB)
- Institute of Cancer Research (GB)
- 3The Institute of Cancer Research, Sutton, United Kingdom;
- ORCID
- Venue
- Cancer Research
- Published
- 2021-07-01
- Volume
- 81
- Issue
- 13_Supplement
- Pages
- CT019-CT019
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W3183056597
- Cited by
- 10
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 5 · 2021: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- KRAS-mutant non-small cell lung cancer, defactinib, RAF/MEK inhibitors, focal adhesion kinase inhibitor, combination therapy, intermittent dosing, MEK inhibitor resistance, KRAS G12V, KRAS G12C, anticancer activity, safety and tolerability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC. https://app.cochat.ai/papers/10.1158/1538-7445.am2021-ct019
- The paper
- Krebs, M. G., Shinde, R., Rahman, R. A., Grochot, R., Little, M., King, J., Kitchin, J., Parmar, M., Turner, A., Mahmud, M., Yap, C., Tunariu, N., Lopez, J., De Bono, J. S., Banerji, U., & Minchom, A. (2021). Abstract CT019: A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC. Cancer Research. https://doi.org/10.1158/1538-7445.am2021-ct019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.